Smoking Cessation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Smoking Cessation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major smoking cessation markets are expected to exhibit a CAGR of 7.32% during 2024-2034.

The smoking cessation market has been comprehensively analyzed in IMARC's new report titled "Smoking Cessation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Smoking cessation is the process of quitting smoking and overcoming nicotine addiction. It involves taking deliberate actions to stop smoking tobacco products, including cigarettes, pipes, or cigars. The goal of smoking cessation is to improve overall health and reduce the associated risks of medical consequences. The withdrawal symptoms of this condition are not experienced by everyone and may vary in severity. Some common indications of smoking cessation include cravings for nicotine, irritation, restlessness, anxiety, mood swings, difficulty concentrating, an increase in appetite and subsequent weight gain, insomnia or trouble falling asleep, fatigue, decreased energy levels, etc. In many cases, patients may also experience coughing, depression, headaches or migraines, intense dreams or nightmares, episodes of dizziness, a feeling of lightheadedness, constipation, indigestion, an upset stomach, muscle aches, joint pain, etc. The healthcare provider may perform various standardized questionnaires and assessments, such as the Fagerstrom Test for Nicotine Dependence (FTND), that allow for the monitoring of progress during smoking cessation interventions and help in determining if patients are becoming less dependent on nicotine.

The rising awareness regarding the detrimental health effects of smoking, including the increased risk of cancer, cardiovascular disease, respiratory problems, etc., is primarily driving the smoking cessation market. Furthermore, the widespread adoption of nicotine-containing products, such as patches, gums, lozenges, inhalers, nasal sprays, etc., to help reduce nicotine cravings and withdrawal symptoms while avoiding the harmful chemicals present in tobacco smoke is acting as another significant growth-inducing factor. In addition to this, the escalating demand for positive lifestyle modifications, including practicing regular exercise, managing stress through relaxation techniques, and fostering a smoke-free environment at home and work, is also bolstering the market growth. Moreover, the inflating utilization of effective drugs, such as bupropion and varenicline, to alleviate the withdrawal symptoms of the condition is further creating a positive outlook for the market. These medications work by reducing cravings or blocking the pleasurable effects of nicotine on the brain, which helps to stabilize mood during the process. Apart from this, the emerging popularity of cognitive-behavioral therapy, owing to its numerous benefits, like preventing relapse and improving the quality of life, is expected to drive the smoking cessation market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the smoking cessation market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for smoking cessation and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the smoking cessation market in any manner.

Recent Developments:
In July 2023, Achieve Life Sciences, Inc. released the findings of the Phase 3 ORCA-2 randomized placebo-controlled clinical trial of cytisinicline as a smoking cessation treatment, the first large-scale testing of this medicine in the US. The researchers found that cytisinicline displayed "smoking cessation efficacy and excellent tolerability" in adult smokers.
In June 2023, NFL BIOSCIENCES stated that the European Patent Office had approved the issuance of its patent (17 716 853.1) for NFL-101, a nicotine-free botanical medicine candidate composed of natural proteins isolated from tobacco leaves, with a primary focus on smoking cessation. This patent will safeguard NFL-101's innovation through 2036 in 17 European countries.

Key Highlights:
Over two-thirds of cigarette smokers desire to quit, and more than half attempt to quit every year.
Nearly 40 million American people smoke, and approximately 70% report that they wish to quit.
It's estimated that only 3 to 5 percent of cigarette smokers who try to quit without aid succeed for 6 to 12 months.
Even with presently accessible treatment options, relapse rates remain higher than 80%.
According to the WHO, smokers who quit smoking reduce their chance of developing type 2 diabetes by as much as 30-40%.

Drugs:
CHANTIX (varenicline) is a prescription medication used by adults to help them quit smoking. Varenicline inhibits nicotine's effects on the brain, reducing the impulse to smoke.

Cytisinicline is a plant-based alkaloid that has a strong affinity for the nicotinic acetylcholine receptor. It can help cure nicotine addiction in smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, lessening the severity of withdrawal symptoms, and decreasing the pleasure and satisfaction associated with nicotine products.

AXS-05 is a new oral NMDA receptor antagonist. It is under development by Axsome Therapeutics for smoking cessation. The therapeutic candidate is made up of dextromethorphan and bupropion utilizing Axsome's metabolic inhibition technology.


Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the smoking cessation market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the smoking cessation market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape:
This report also provides a detailed analysis of the current smoking cessation marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:
Market Insights

How has the smoking cessation market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the smoking cessation market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the smoking cessation market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of smoking cessation across the seven major markets?
What is the number of prevalent cases (2018-2034) of smoking cessation by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of smoking cessation by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with smoking cessation across the seven major markets?
What is the size of the smoking cessation patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of smoking cessation?
What will be the growth rate of patients across the seven major markets?

Smoking Cessation: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for smoking cessation drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the smoking cessation market?
What are the key regulatory events related to the smoking cessation market?
What is the structure of clinical trial landscape by status related to the smoking cessation market?
What is the structure of clinical trial landscape by phase related to the smoking cessation market?
What is the structure of clinical trial landscape by route of administration related to the smoking cessation market?